최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기소아청소년정신의학 = Journal of the Korean Academy of Child and Adolescent Psychiatry, v.27 no.1, 2016년, pp.31 - 38
박소영 (고려대학교 의과대학 정신건강의학교실 소아청소년정신과) , 이소영 (순천향대학교 의과대학 순천향대학교 부천병원 정신건강의학교실) , 이문수 (고려대학교 의과대학 정신건강의학교실 소아청소년정신과)
Pharmacotherapy is considered the first line therapy in attention-deficit hyperactivity disorder (ADHD). Many patients also choose complementary medicine such as dietary supplements. Omega-3 has shown some efficacy for improving ADHD symptoms in several studies. The goal of this review is to integra...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
ADHD 치료를 위한 정신자극제의 부작용은 무엇인가? | 그러나 전체 ADHD 환자의 20-30%에서는 정신자극제의 효과가 미미하거나 충분하지 못하며, 식욕 부진, 수면의 질 저하 등의 부작용을 나타내고 있다. 10,11) 또한 부모들은 자녀에게 향정신성약물을 복용하게 하는 것을 일종의 낙인 효과로 간주하여 약물 복용을 주저하는 경향이 있다. | |
주의력결핍 과잉행동장애란 무엇인가? | 주의력결핍 과잉행동장애(attention-deficit hyperactivity disorder, ADHD)는 주의력의 결핍 및 과잉행동과 충동성 등의 증상을 특징적으로 나타내는 질환으로, 주로 소아기에 발병하여 성인기까지 지속되어 대인관계, 학업성취도 및 정신 건강에 영향을 미친다. 1-3) ADHD 아동의 치료 중 근거 중심 치료(evidence based treatment)로 가장 널리 사용되는 방법은 약물 치료이다. | |
주의력결핍 과잉행동장애의 치료 중 중심치료로 가장 널리 사용되는 방법은 무엇인가? | 주의력결핍 과잉행동장애(attention-deficit hyperactivity disorder, ADHD)는 주의력의 결핍 및 과잉행동과 충동성 등의 증상을 특징적으로 나타내는 질환으로, 주로 소아기에 발병하여 성인기까지 지속되어 대인관계, 학업성취도 및 정신 건강에 영향을 미친다. 1-3) ADHD 아동의 치료 중 근거 중심 치료(evidence based treatment)로 가장 널리 사용되는 방법은 약물 치료이다. 그중에서도 메틸페니데이트(methylpheni-date) 등의 정신자극제에 반응하는 ADHD 아동이 전체의 70% 이상으로, 이는 그 효과성이 많은 연구들에서 입증되어 왔다. |
Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics. Pediatrics 2000;105:1158-1170.
Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998;279:1100-1107.
Cho SC. Concept and biological study of attention deficit hyperactivity disorder. J Korean Acad Child Adolesc Psychiatry 1990;1:5-26.
Ahn DH, Hong KE. Management of the child with attention - deficit hyperactivity disorders (ADHD). J Korean Acad Child Adolesc Psychiatry 1990;1:77-88.
Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996;35:409-432.
Yang YH, Yoo HJ. Stimulants medication of attention-deficit hyperactivity disorder. J Korean Acad Child Adolesc Psychiatry 2008;19:61-71.
Lewis M. Child and adolescent psychiatry: a comprehensive textbook. Philadelphia, PA: Lippincott Williams & Wilkins;2002.
Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999;38:1551-1559.
Cheng JY, Chen RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 2007;194:197-209.
Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A metaanalysis. CMAJ 2001;165:1475-1488.
Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990;86:184-192.
Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001;40:168-179.
Yoo HJ, Yang SJ, Shin D, Kang H, Kim BN, Kim JH, et al. The Korean practice parameter for the treatment of attention-deficit hyperactivity disorder(III): pharmacologic treatment. J Korean Acad Child Adolesc Psychiatry 2007;18:16-25.
Conners CK, Epstein JN, March JS, Angold A, Wells KC, Klaric J, et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. J Am Acad Child Adolesc Psychiatry 2001;40:159-167.
Berger I, Dor T, Nevo Y, Goldzweig G. Attitudes toward attentiondeficit hyperactivity disorder (ADHD) treatment: parents' and children's perspectives. J Child Neurol 2008;23:1036-1042.
Dunnick JK, Hailey JR. Experimental studies on the long-term effects of methylphenidate hydrochloride. Toxicology 1995;103:77-84.
Pelham WE Jr, Waschbusch DA. Behavioral intervention in attention- deficit/hyperacivity disorder. In: Quay HC, Hogan AE, editors. Handbook of disruptive behavior disorders. New York: Springer; 1999. p.255-278.
Kim BN, Yoo HK, Kang H, Kim JH, Shin D, Ahn D, et al. The Korean practice parameter for the treatment of attention-deficit hyperactivity disorder (IV): non-pharmacologic treatment. J Korean Acad Child Adolesc Psychiatry 2007;18:26-30.
Safren SA, Sprich S, Mimiaga MJ, Surman C, Knouse L, Groves M, et al. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA 2010;304:875-880.
Pelham WE Jr, Wheeler T, Chronis A. Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychol 1998;27:190-205.
Barkley RA, DuPaul GJ, McMurray MB. Comprehensive evaluation of attention deficit disorder with and without hyperactivity as defined by research criteria. J Consult Clin Psychol 1990;58:775-789.
Bourre JM. Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 1: micronutrients. J Nutr Health Aging 2006;10:377-385.
Fernstrom JD. Can nutrient supplements modify brain f unction? Am J Clin Nutr 2000;71(6 Suppl):1669S-1675S.
Sarris J, Kean J, Schweitzer I, Lake J. Complementary medicines (herbal and nutritional products) in the treatment of attention deficit hyperactivity disorder (ADHD): a systematic review of the evidence. Complement Ther Med 2011;19:216-227.
Arnold LE, Hurt E, Lofthouse N. Attention-deficit/hyperactivity disorder: dietary and nutritional treatments. Child Adolesc Psychiatr Clin N Am 2013;22:381-402, v.
Rucklidge JJ, Johnstone J, Kaplan BJ. Nutrient supplementation approaches in the treatment of ADHD. Expert Rev Neurother 2009;9:461-476.
Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J Dev Behav Pediatr 2007;28:82-91.
Gustafsson PA, Birberg-Thornberg U, Duchen K, Landgren M, Malmberg K, Pelling H, et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatr 2010;99:1540-1549.
Perera H, Jeewandara KC, Seneviratne S, Guruge C. Combined ${\omega}3$ and ${\omega}6$ supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double- blind, placebo-controlled study. J Child Neurol 2012;27:747-753.
Yehuda S, Rabinovitz-Shenkar S, Carasso RL. Effects of essential fatty acids in iron deficient and sleep-disturbed attention deficit hyperactivity disorder (ADHD) children. Eur J Clin Nutr 2011;65:1167-1169.
Richardson AJ, Puri BK. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:233-239.
Vaisman N, Kaysar N, Zaruk-Adasha Y, Pelled D, Brichon G, Zwingelstein G, et al. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. Am J Clin Nutr 2008;87:1170-1180.
Manor I, Magen A, Keidar D, Rosen S, Tasker H, Cohen T, et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. Eur Psychiatry 2012;27:335-342.
Milte CM, Parletta N, Buckley JD, Coates AM, Young RM, Howe PR. Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. Nutrition 2012;28:670-677.
Stevens L, Zhang W, Peck L, Kuczek T, Grevstad N, Mahon A, et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 2003;38:1007-1021.
Raz R, Carasso RL, Yehuda S. The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 2009;19:167-177.
Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC, Heird WC. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr 2001;139:189-196.
Johnson M, Ostlund S, Fransson G, Kadesjo B, Gillberg C. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. J Atten Disord 2009;12:394-401.
Belanger SA, Vanasse M, Spahis S, Sylvestre MP, Lippe S, L'heureux F, et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatr Child Health 2009;14:89-98.
Aman MG, Mitchell EA, Turbott SH. The effects of essential fatty acid supplementation by Efamol in hyperactive children. J Abnorm Child Psychol 1987;15:75-90.
Arnold LE, Kleykamp D, Votolato NA, Taylor WA, Kontras SB, Tobin K. Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biol Psychiatry 1989;25:222-228.
Hirayama S, Hamazaki T, Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. Eur J Clin Nutr 2004;58:467-473.
Raz R, Gabis L. Essential fatty acids and attention-deficit-hyperactivity disorder: a systematic review. Dev Med Child Neurol 2009; 51:580-592.
Hawkey E, Nigg JT. Omega-3 fatty acid and ADHD: blood level analysis and meta-analytic extension of supplementation trials. Clin Psychol Rev 2014;34:496-505.
Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 1991;54:438-463.
Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002;21:495-505.
Stevens LJ, Zentall SS, Deck JL, Abate ML, Watkins BA, Lipp SR, et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr 1995;62:761-768.
Antalis CJ, Stevens LJ, Campbell M, Pazdro R, Ericson K, Burgess JR. Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2006;75:299-308.
Joshi K, Lad S, Kale M, Patwardhan B, Mahadik SP, Patni B, et al. Supplementation with flax oil and vitamin C improves the outcome of attention deficit hyperactivity disorder (ADHD). Prostaglandins Leukot Essent Fatty Acids 2006;74:17-21.
Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids 2006;75:259-269.
Drane DL, Logemann JA. A critical evaluation of the evidence on the association between type of infant feeding and cognitive development. Paediatr Perinat Epidemiol 2000;14:349-356.
Belfort MB, Rifas-Shiman SL, Kleinman KP, Guthrie LB, Bellinger DC, Taveras EM, et al. Infant feeding and childhood cognition at ages 3 and 7 years: effects of breastfeeding duration and exclusivity. JAMA Pediatr 2013;167:836-844.
Arnold LE, Kleykamp D, Votolato N, Gibson RA, Horrocks L. Potential link between dietary intake of fatty acids and behavior: pilot exploration of serum lipids in attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 1994;4:171-182.
Brue AW, Oakland TD, Evans RA. The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Sci Rev Altern Med 2001;5:187-194.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.